Medicare AdvantageAdministrativeLow impact
MA08.023c, Enzyme Replacement for the Treatment of Gaucher's Disease
Independence Blue Cross·Endocrinology, Hematology, Oncology +1 more·Medical Policy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.023c for enzyme replacement therapy in Gaucher's disease has been reissued effective May 28, 2025. This is a policy reissue rather than a substantive change, but billing teams should verify current coverage criteria and documentation requirements for Gaucher disease treatments.
Action Required
By May 28, 2025: Review updated policy MA08.023c for enzyme replacement therapy coverage criteria for Gaucher's disease patients on Medicare Advantage plans. Verify current prior authorization requirements and documentation standards remain unchanged from previous version.